New strategies for imaging brain-related therapy

In chapter 2, focused ultrasound (FUS) could be useful to improve the drug delivery in the brain, however, no clinical evidence that FUS could replace other methods is currently available. Positron emission tomography (PET) studies are required to understand the mechanism of opening the blood brain barrier (BBB)with FUS .
Chapter 3, evaluates the pharmacokinetic modeling of [18 F]MC225 in non-human primates to assess P-gp function at different scan durations. Long dynamic scan of 60 min was optimal for two tissue compartmental model (2TCM), and in one tissue compartmental model, a short scan of 10–30 min was better.
Chapter 4, pharmacokinetic modeling of [18F] MC225 in humans was evaluated to quantify P-gp function at the BBB. 2TCM for plasma metabolites appears to be the optimal model to describe P-gp function in humans.
Chapter 5, compares between the gold standard Oxygen-15-labelled water [15O H2O]-PET and multi-echo dynamic susceptibility contrast - magnetic resonance imaging ( DSC-MRI ) in measuring cerebral blood flow (CBF) in healthy volunteers. DSC-MRI derived CBF measurements normalized to white-matter showed reasonable agreement with those obtained by [15O]H2O-PET in regions throughout the brain.
Chapter 6, [18F]fluorodeoxyglucose ([18F]FDG) was able to detect the effect of radiation dose on selected brain regions and monitor the uptake changes before and after proton therapy even 3 months after completion of intensity modulated proton therapy for nasopharyngeal carcinoma survivors.